Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

247
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
247
Introduction to Hemostasis01:05

Introduction to Hemostasis

12.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
12.9K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

169
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
169
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diastolic blood pressure and end-tidal carbon dioxide during adult ICU cardiopulmonary resuscitation: association with return of spontaneous circulation.

Resuscitation·2026
Same author

Noise quantification in the intensive care unit of a tertiary care hospital.

World journal of critical care medicine·2026
Same author

Gender equality and equity in intensive care: an international Delphi consensus study.

Intensive care medicine·2026
Same author

Seed inoculation with Rhizobium and integrated nutrient management influences the productivity of groundnut and their residual impact on finger millet.

Scientific reports·2026
Same author

Role of Adjunctive corticoSTEROIDs on clinical outcomes in severe Scrub typhus pneumonitis: ASTEROIDS study protocol - a randomised controlled trial.

BMJ open·2025
Same author

The Impact of Inflammatory Biomarker Subphenotypes on Acute Respiratory Distress Syndrome Prognosis: A Systematic Review and Meta-analysis.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine·2025

Related Experiment Video

Updated: Jan 5, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.5K

Hemostatic Agents in Critically Ill Patients.

Saurabh Kumar Das1, Maheeja Maddi Reddy1, Sumit Ray1

  • 1Department of Critical Care, Artemis Hospital, Gurugram, Haryana, India.

Indian Journal of Critical Care Medicine : Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine
|October 29, 2019
PubMed
Summary
This summary is machine-generated.

This study reviews hemostatic agents for critically ill patients. It highlights their role in managing bleeding emergencies in intensive care settings.

More Related Videos

Integrated Compensatory Responses in a Human Model of Hemorrhage
07:57

Integrated Compensatory Responses in a Human Model of Hemorrhage

Published on: November 20, 2016

13.0K
Fixed Volume or Fixed Pressure: A Murine Model of Hemorrhagic Shock
16:31

Fixed Volume or Fixed Pressure: A Murine Model of Hemorrhagic Shock

Published on: June 6, 2011

25.5K

Related Experiment Videos

Last Updated: Jan 5, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.5K
Integrated Compensatory Responses in a Human Model of Hemorrhage
07:57

Integrated Compensatory Responses in a Human Model of Hemorrhage

Published on: November 20, 2016

13.0K
Fixed Volume or Fixed Pressure: A Murine Model of Hemorrhagic Shock
16:31

Fixed Volume or Fixed Pressure: A Murine Model of Hemorrhagic Shock

Published on: June 6, 2011

25.5K

Area of Science:

  • Critical care medicine
  • Pharmacology
  • Hematology

Background:

  • Critically ill patients often experience coagulopathy and bleeding complications.
  • Hemostatic agents are crucial for managing life-threatening hemorrhage in intensive care units (ICUs).
  • Understanding the efficacy and safety of these agents is vital for patient outcomes.

Purpose of the Study:

  • To provide a comprehensive overview of hemostatic agents used in critical care.
  • To discuss the mechanisms of action, indications, and contraindications of various hemostatic agents.
  • To evaluate the current evidence supporting the use of hemostatic agents in critically ill patients.

Main Methods:

  • Literature review of studies on hemostatic agents in critically ill patients.
  • Analysis of clinical trials and observational studies evaluating hemostatic agent efficacy.
  • Synthesis of data on patient populations, dosages, and outcomes.

Main Results:

  • Hemostatic agents, including procoagulants and antifibrinolytics, demonstrate variable efficacy.
  • Early administration and appropriate patient selection are key to successful hemostasis.
  • Adverse events associated with hemostatic agents require careful monitoring.

Conclusions:

  • Hemostatic agents are indispensable tools in managing bleeding in critically ill patients.
  • Further research is needed to optimize the use of hemostatic agents and define specific protocols.
  • Personalized approaches considering patient-specific factors are essential for effective hemostasis.